Dr Filip Janku speaks to ecancer about the interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor; a topic which was presented at this year’s virtual ENA 2-20 conference.
He initially explains the rationale behind this study and then mentions some of the methodology used in this study.
He says that the drug in question seems effective but the optimum dosage must now be decided.
Dr Janku says that this is a phase 1 trial and more research would be required before this drug becomes functional but we are headed towards the right direction.
He winds it up, by talking about the future of this study.